Indian pharmaceutical giants, including Sun Pharma and Cipla, are bracing for a major shift in trade policy as the United States introduces a rigorous tariff schedule for generic medicines.
President Donald Trump recently announced a phased transition that will permit a two-year exemption period before aggressive duties—ranging from 100% to 200%—take effect on foreign-manufactured drugs beginning in 2028.
Market Implications
The announcement has sparked immediate concern among investors, as the U.S. represents the largest export market for many Indian drug manufacturers. The prospect of these elevated costs threatens to erode margins and alter the competitive landscape for affordable medicine providers.
Strategic Response
- Analysts suggest companies may need to accelerate local manufacturing investments within the U.S.
- Supply chain diversification is expected to become a top priority for pharmaceutical boards.
- Short-term volatility is likely as firms assess the long-term impact on global revenue streams.
While the two-year grace period provides a temporary cushion, the industry must now pivot to navigate a more protectionist trade environment that could reshape how essential generics reach American patients.
